Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

567.74 +7.98 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
52 53 Next >
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients. 
Via Investor's Business Daily
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Biotech Stocks That Could Help Set You Up for Life
The two companies have seen similar share growth over the past year. 
Via The Motley Fool
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
Via Benzinga
Regeneron Pharmaceuticals's Earnings Outlook
Via Benzinga
2 Top Healthcare Stocks Defying the Bear Market
These companies have impeccable long-term investment theses. 
Via The Motley Fool
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
New 52-Week Highs In 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023. 
Via Talk Markets
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Via Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Via Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Via Benzinga
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential. 
Via InvestorPlace
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report. 
Via Investor's Business Daily
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each... 
Via Benzinga
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Most Undervalued Stocks to Buy in February 2023
These undervalued stocks to buy are under-appreciated, and have substantial upside as we move deeper into the new year. 
Via InvestorPlace
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy. 
Via InvestorPlace
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback